Sanofi nabs EU approval for Toujeo; Shire defends ultralow tax rate;

@FiercePharma: Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Would any of you guys want to read a special report entitled "The secret first initials of biopharma CEOs and what they stand for"...? | Follow @CarlyHFierce

> Sanofi ($SNY) won European approval for its new basal insulin, Toujeo, intended as a follow-up to the blockbuster Lantus treatment that could face biosimilar competition this year. Release

> Dublin-based Shire ($SHPG) called its tax practices "mainstream" among multinational companies, in answer to shareholder questions about its $56 million 2014 tax bill, on $3.4 billion in profits. Report

> At least one analyst figures Teva's ($TEVA) Mylan ($MYL) bid would pay off even at a price of $100 per share, the figure Mylan quoted as a minimum starting point for negotiations. Report

> MannKind ($MNKD) is adding a 12-unit cartridge to its Afrezza line-up, a set of inhaled insulin products marketed by Sanofi. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Two U.S. hospitals to test startup's novel medical device malware detection software. Article | Follow @FierceMedDev

@VarunSaxena2: FDA bans manufacturing of Medtronic's infusion pump, citing violation of quality system regs. News | Follow @VarunSaxena2

@EmilyWFierce: Scanadu ropes in $35M for smartphone tricorder diagnostic device. More | Follow @EmilyWFierce

> Belgian molecular Dx player Biocartis raises €100M to advance recent launch of Idylla system. Story

> 'Stealthy' Medina raises $6M in debt for cerebral aneurysm device after CE mark last fall. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Celgene bags a build-to-buy biotech in $485M cancer deal. Report | Follow @FierceBiotech

@JohnCFierce: Biogen CEO Scangos commits $2.5B to a high stakes Alzheimer's gamble. More | Follow @JohnCFierce

> Resverlogix gets a $116M China drug development deal, stokes buyout buzz. More

> FDA bats down Merck's sugammadex in third rejection. Item

> Galapagos' arthritis drug shines in another PhIIb study as M&A rumors simmer. Article

Drug Delivery News

> Presage's multiple-cancer-drug injection device shows promising first-in-human results. Story

> Topical gel for migraine shows promise in trials, can penetrate transdermal barrier. Item

> 3M says its new intravenous port dressing will make drug delivery easier and fight off site infections. Report

> AbbVie's FDA-approved Duopa gel for Parkinson's skates through yearlong study. Story

> Generex announces second medical marijuana outlicensing deal for its drug delivery tech. Article

Pharma Manufacturing News

> Texas cancer center guilty of selling foreign-made Avastin. Item

> Wockhardt recalling all pre-ban products still in the U.S. More

> Mylan recalls injected cancer meds made for Pfizer. Story

> GSK licks Nicorette manufacturing problems; 'Minis' are back. Article

> Lilly's Elanco to unload former Novartis vax plant. News

Pharma Asia News

> Eisai, Nihon Medi-Physics plan work on dementia with Lewy bodies. Report

> India mulls adopting international standards on drug inspections, manufacturing. Story

> Cipla leans toward compromise in India court case over Onbrez from Novartis. More

> Japan's Panasonic joins Toshiba in rush to medical devices. Article

> Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. Item

And Finally... Suspected bird flu cases have popped up in 5 Iowa poultry farms, affecting some 6 million birds. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.